Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Health Behaviour Change

Accelerating Generation of Payer Insights & Evidence Across the Lifecycle to Achieve Optimal Access

Genesis Research Group

ISPOR Europe: Generating Payer Insights & Evidence: Meeting the Challenges of New Evidence Paradigm

Genesis Research Group

Accelerating Generation of Payer Insights & Evidence Across the Lifecycle to Achieve Optimal Access

Genesis Research Group

Dom Marchant

Dom Marchant, Chief Creative Officer, joins the executive leadership team at OPEN Health with a new vision to drive the creative communications practice

Dom Marchant, Chief Creative Officer, joins the executive leadership team at OPEN Health with a new vision to drive the creative communications practice

OPEN Health

- PMLiVE

Pfizer’s pentavalent meningococcal vaccine granted FDA approval

Penbraya helps protect against the five most common meningococcal serogroups

- PMLiVE

Roche to acquire Telavant in deal worth over $7.1bn

The drugmaker will gain access to an experimental treatment for inflammatory bowel disease

- PMLiVE

Merck shares positive results for Keytruda in early-stage breast cancer

Approximately 298,000 people will be diagnosed with breast cancer in the US this year

- PMLiVE

Preparing for the clinical trials of the future

With access to more data than ever before, now is the time for the industry to modernise, become data-led and boost patient experience

- PMLiVE

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Inizio

- PMLiVE

FREE Live Webinar – Solving your patient recruitment & retention challenges – 15th November 2023

Join Innovative Trials and Avillion in this FREE webinar

Innovative Trials

- PMLiVE

A New Era in Patient Recruitment & Retention

Innovative Trials launches ‘first of its kind’ service to boost clinical trial patient recruitment and retention .

Innovative Trials

- PMLiVE

Merck and Daiichi Sankyo announce ADC agreement worth up to $22bn

The companies will jointly develop and commercialise three of Daiichi Sankyo’s cancer candidates

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links